Demand for health care services in Gulf Cooperation Council (GCC) member states is on a strong upward trajectory despite the global economic downturn, according to a new report from IHS Global Insight by analyst Aparna Krishnan.
Expansion in the sector will gather pace over the next 20 years; public, private and foreign direct investment will grow in response to population growth, shifting disease profiles and changes to healthcare delivery and financing. IHS Global Insight explores the reasons behind the rise in healthcare investments and its impact on the pharmaceutical industry, noting the following:
Key findings
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze